share_log

B of A Securities Maintains Buy on Travere Therapeutics, Lowers Price Target to $18

B of A Securities Maintains Buy on Travere Therapeutics, Lowers Price Target to $18

美国银行证券维持对Travere Therapeutics的买入评级,并将目标股价下调至18美元
Benzinga ·  09/27 07:17  · 评级/大行评级

B of A Securities analyst Greg Harrison maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and lowers the price target from $19 to $18.

美国银行证券分析师Greg Harrison认为Travere Therapeutics (纳斯达克:TVTX) 值得买入并将目标价从19美元下调至18美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发